|
Printable version |
From: | "G Stolwyk" <stolwyk@wave.co.nz> |
Date: | Sun, 17 Nov 2002 08:49:26 +1300 |
This is an
Australian stock.
We are still in an
accumulation phase: $1.97.
There won't be news for a while but that could suddenly change. NRT is gearing up for the Phenoxodial trials, one has already started in Australia. Sofar it has been found that in 2 cases, breast cancer and prostate, oral administration will arrive at the source of the problem. However, NRT has now NV563, a multi-compound drug (di-mer). This is much stronger than its predecessor: NV050. Oral administration doesn't work in the treatment of Leukemias and here
intravenous injection will do. I am interested in the latter as well as drug NV5063. Generaly spoken, these Phase II trials will finish on 30 June, next year. However, we could have reports on the Phenoxodial stand-alone trials perhaps in Jan/Febr. Gerry |
|